146 related articles for article (PubMed ID: 24410431)
1. Antiangiogenic agents in natural products for the treatment of gynecologic disorders.
Aghamohammadi A; Hosseinimehr SJ
Nutr Cancer; 2014; 66(2):206-13. PubMed ID: 24410431
[TBL] [Abstract][Full Text] [Related]
2. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
3. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic phytochemicals and medicinal herbs.
Jeong SJ; Koh W; Lee EO; Lee HJ; Lee HJ; Bae H; Lü J; Kim SH
Phytother Res; 2011 Jan; 25(1):1-10. PubMed ID: 20564543
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
Frumovitz M; Sood AK
Gynecol Oncol; 2007 Mar; 104(3):768-78. PubMed ID: 17306693
[TBL] [Abstract][Full Text] [Related]
7. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
8. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
9. Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling.
Huang S; Yang N; Liu Y; Hu L; Zhao J; Gao J; Li Y; Li C; Zhang X; Huang T
Nutr Res; 2012 Jul; 32(7):530-6. PubMed ID: 22901561
[TBL] [Abstract][Full Text] [Related]
10. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
11. Angiotherapeutics from natural products: from bench to clinics?
Bernas G
Clin Hemorheol Microcirc; 2003; 29(3-4):199-203. PubMed ID: 14724342
[TBL] [Abstract][Full Text] [Related]
12. VEGF as a key mediator of angiogenesis in cancer.
Carmeliet P
Oncology; 2005; 69 Suppl 3():4-10. PubMed ID: 16301830
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
Limaverde-Sousa G; Sternberg C; Ferreira CG
Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds.
Ebrahim HY; El Sayed KA
Mar Drugs; 2016 Mar; 14(3):. PubMed ID: 26978377
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
18. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis.
Ricci AG; Olivares CN; Bilotas MA; Meresman GF; Barañao RI
Reprod Sci; 2011 Jul; 18(7):614-22. PubMed ID: 21266664
[TBL] [Abstract][Full Text] [Related]
19. Use of angiogenesis inhibitors in tumour treatment.
Fayette J; Soria JC; Armand JP
Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]